Articles

KEYNOTE-181 results show improved overall survival in patients with advanced esophageal cancer treated with second-line pembrolizumab compared with chemotherapy. Read More ›

Recommendations for the clinical management of patients with advanced esophageal cancer and gastroesophageal junction adenocarcinoma were released by an expert panel. Read More ›

Differences in survival time by tumor response were found during evaluation of nivolumab therapy in advanced gastric cancer. Read More ›

The use of PET to direct therapy after nonresponse to induction chemotherapy improved overall survival in patients with resectable esophageal cancer. Read More ›

Promising response rates were reported in a clinical trial of neoadjuvant sintilimab with CapeOx in patients with resectable, locally advanced gastric/gastroesophageal junction (GEJ) cancer. Read More ›

MAHOGANY Cohort A clinical trial results reveal margetuximab and retifanlimab combination treatment led to tumor response with an acceptable safety profile. Read More ›

An early-phase clinical trial of nivolumab with radiotherapy in patients with relapsed unresectable/recurrent gastric cancer demonstrated prolonged patient survival. Read More ›

Statistically meaningful improvement in progression-free survival, overall survival, and objective response rate was found in patients with advanced gastric cancer treated with bemarituzumab and modified FOLFOX6. Read More ›

Overall survival and progression-free survival were improved with first-line treatment of camrelizumab with chemotherapy in patients with advanced or metastatic esophageal squamous-cell carcinoma (ESCC). Read More ›

This edition of Year in Review is focused on gastric cancer, esophageal cancer, and gastroesophageal junction (GEJ) cancer, and immunotherapy and targeted therapies used in the management of these cancers. Read More ›